usatoday24
Things are not going well for Novo Nordisk, the Danish pharmaceutical Ozempic and Wegovythe popular Drugs to lose weight. The company fell up to 30% in the stock market After presenting (bad) results. In the last year, the shares have fallen double, 60%.
Although it will continue to grow, it has trimmed its expectations: from a growth in predicted income between 13% and 21% for annual sales, the company has dropped its fork to 8% and 14%. It is just a consequence of what is already living in several markets.
Sorpasso. Novo Nordisk had been in a vulnerable situation, and its stock market value, which came to rise 400% from the pandemic, is reflecting what is already happening in the recipe market: according to the Financial Timesthe IQVIA research company reports that the Danish company has been destroyed in market share in the United States by the pharmaceutical company Eli Lilly, its great rival worldwide.
A painful loss in the largest market. With 607,000 weekly recipes, Ozempic has fallen below 622,000 Mounjaro, Lilly’s drug. Ozempic has dropped from 50% of sales for the first time, despite the fact that a judge of the Texas district prohibited the country in the country Marketing of Copies of Novo Nordisk products. For Novo, it means losing the leadership in the market where more semaglutida sells Worldwide: in 2023, 71% of sales arrived from the United States.
The news adds to another negative: Wegovy had already been overcome by another proposal by Lilly: Zepbound. It was seen coming: in the United Kingdom, Mounjaro already exceeded Wegovy At the end of the year. The CEO of Chemist4u, an online pharmacy, said that in the last three or four months of 2024, Mounjaro won Wegovy in a 70-30.
What are Zepbound and Mounjaro. Zepbound was the second commercial name that Lilly put to the Tirzepatidathe compound with which Lilly threw himself to compete against type 2 diabetes, such as Ozempic. If Novo Nordisk launched Wegovy to focus on weight loss as an alternative for the diabetic ozempic approach using the semaglutida, Lilly did the same with Zepbound with respect to Mounjaro.
The FDA approved Zepbound’s medical use at the end of 2023. In Spain, it has not been approved for now, but for a year Pharmacies market Mounjaro under prescription for diabetes and obesity.
This is how Novo Nordisk lost his advantage. The arrival of Danish pharmaceutical drugs to the United States was marked by a production that failed to meet the spectacular demand. According to Financial Times, Evan Seigerman, BMO capitalist Markets, prognosis problems had to do with a previous medication from Novo, SaxendaIt was not so successful.
The supply problems led to the approved the Sale of Ozempic copies. Although Novo Nordisk managed to increase production by acquiring factories, the under supply gave Lilly time, which Mounjaro launched for diabetes in 2022 and Zepbound in 2023.
A matter of marketing. When the huge success of Ozempic began, Novo Nordisk went from being a company focused on the sale of insulin that had to convince doctors through research to have to aim at the weight loss market, a massive market focused on the final consumer, and highly influenced by advertising and celebrities.
Novo left the door open to Lilly, and Bernie helped. The marketing of the American pharmaceutical He started selling his online drugs. Being also Aggressive with discounts and several price drops. In this sense, Senator Bernie Sanders also did not help will report price differences of Ozempic in the United States compared to other countries ($ 600 per month for 59 of Germany), claiming that generic versions could be sold for less than $ 100, and accusing Novo of using the US market of “dairy cow“
Lilly tests that show advantage over Novo. According to the study results Surmount-5 Posted by Lilly, at 72 weeks, patients who took Zepbound lost 22.8 kilos in front of 15 kilos of those who took Wegovy. A 20.2% weight loss using the lilly tirzepatida versus 13% of the Semaglutida of Novo. With regard to diabetes, the essay Surpass-3 He showed that Mounjaro produced a reduction in glucosylated hemoglobin (A1C) between 2 and 2.3%, compared to 1.9% of Ozempic.
A new (and something frustrated) hope. Novo is developing New Generation Drugswith a drug called to be the successor of Wegovy: Cagrisema. The problem with this drug is that initially, the company announced that it hoped to help patients lose 25% of their weight.
The result of his trial provided somewhat minor general figures, With 22.7% loss in 68 weeks. 40.4% of the patients who received the dose of Cagrisema did reach 25% loss in that period, but the market was relentless and fruit of the disappointment between investors.
GIPHY App Key not set. Please check settings